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The crystallization of three catalytically inactive mutants of penicillin V acylase
(PVA) from Bacillus sphaericus in precursor and processed forms is reported.
The mutant proteins crystallize in different primitive monoclinic space groups
that are distinct from the crystal forms for the native enzyme. Directed mutants
and clone constructs were designed to study the post-translational autoproteo-
lytic processing of PVA. The catalytically inactive mutants will provide three-
dimensional structures of precursor PVA forms, plus open a route to the study of
enzyme±substrate complexes for this industrially important enzyme.
1. Introduction
Penicillin V acylase (PVA) from Bacillus sphaericus (Pundle &
SivaRaman, 1997) is a homotetrameric protein of 37.5 kDa subunits.
It is industrially used in the hydrolysis of penicillin V to produce
6-aminopenicillanic acid (6-APA), which is the precursor molecule
for semi-synthetic -lactam antibiotics (Shewale & Sudhakaran,
1997). The crystal structure of PVA (Suresh et al., 1999) placed this
protein in the N-terminal nucleophile (Ntn) hydrolase superfamily
(Brannigan et al., 1995). The structures of this family share a char-
acteristic  fold, with the catalytic centre being the side chain of
an amino-terminal residue (Cys, Ser or Thr) incorporated in the
central -sheet as the nucleophile for catalytic attack at the carbonyl
C atom of the substrate. Currently known Ntn hydrolases (Pei &
Grishin, 2003) include proteins that are active on a range of
substrates and that display diverse quaternary organizations.
However, all share the common feature that the active-site nucleo-
phile must be unmasked by a post-translational processing event. In
the crystal structure of PVA, which is a single chain, the active-site
cysteine was found to be the N-terminal residue (Suresh et al., 1999),
whereas the gene encoding PVA has an extra tripeptide (Met-Leu-
Gly) as part of the reading frame preceding cysteine (Olsson &
Uhlen, 1986). The presence of Cys at the N-terminus is explained by
assuming that PVA has undergone post-translational modi®cation to
remove the pro-sequence, similar to that observed in other
mechanistically related enzymes such as penicillin G acylase (PGA)
from Escherichia coli (Duggleby et al., 1995) and cephalosporin
acylase (CPA; Kim et al., 2000). However, this processing event is
simpler in PVA compared with that in PGA and CPA, as in both of
the latter systems a spacer peptide is removed from the middle of the
peptide chain (Hewitt et al., 2000; Kim et al., 2002, 2003) whereby the
polypeptide chain of the active enzyme splits into two.
We have designed clone constructs and site-directed mutants that
were predicted to lead to PVA-processing defects by substitution of
the active-site Cys in the presence of the tripeptide pro-sequence.
Superposition of the PVA and PGA structures suggest a conserved
topology for the `oxyanion-hole' residue that balances the negative
charge on the tetrahedral reaction intermediate. Substitution of this
residue in PVA (Asn175) with alanine was performed to mimic the
study on PGA B-chain residue Asn241, which allowed processing to
occur but yielded a catalytically inactive protein (McVey et al., 2001).
Mutants were also prepared that lacked the PVA pro-sequence. It
was presumed that the initiator formylmethionine residue could be
removed by a methionine aminopeptidase, thus unmasking the
nucleophile in a manner similar to glutamine 5-phosphoribosyl-
1-pyrophosphate amidotransferase from B. subtilis (Smith et al.,
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1994) and so bypass normal PVA processing. These designed mutants
were overexpressed in E. coli, puri®ed, crystallized and characterized
using X-ray crystallographic techniques to probe the mechanism of
autoproteolytic post-translational processing of PVA.
2. Materials and methods
2.1. Cloning
The PVA gene and ¯anking DNA sequence from B. sphaericus
NCIMB 9370 was ampli®ed from chromosomal DNA by PCR using
oligonucleotide primers that incorporated the restriction-endo-
nuclease sites BamHI and EcoRI at the termini of the 1164 bp PCR
fragment. Digested PCR product was cloned into the phagemid
pBluescript SK such that the gene encoding PVA was placed down-
stream of the lac promoter. The DNA sequence was consistent with
that reported (Olsson & Uhlen, 1986) except for a C to G transver-
sion that alters the coding sequence at position 98 of the mature
protein and leads to an amino-acid substitution (ACA Thr to AGA
Arg). This construct was used as a template to prepare the precursor
mutants Pre-Asn175Ala (Pre-N175A), Pre-Cys1Ser (Pre-C1S) and
Pre-Cys1Ala (Pre-C1A) using the QuikChange site-directed muta-
genesis kit (Stratagene). Mutants lacking the three-amino-acid pre-
sequence were cloned into pET vectors and expressed in E. coli
BL21(DE3) cells. The mutants N175A and C1S were produced with a
C-terminal histidine tag to aid puri®cation.
2.2. Expression and purification
Protein expression was performed by growing the transformed
E. coli cells at a temperature of 310 K in Luria±Bertani medium
containing kanamycin (30 mg mlÿ1) for pET-based plasmids and
ampicillin (100 mg mlÿ1) for the pBS phagemids. When the OD660 of
the culture reached about 0.6, IPTG was added to a ®nal concen-
tration of 1 mM. The cells were harvested 4 h post-induction and
disrupted using sonication. After centrifugation, the supernatant was
mixed with streptomycin sulfate to remove nucleic acids and
56%(w/v) ammonium sulfate (AS) was added. Precipitated protein
was dissolved in a minimum volume of buffer (0.05 M sodium
phosphate pH 6.5, 10 mM EDTA) and dialyzed overnight. AS was
added to the dialyzed protein to a ®nal concentration of 24%(w/v)
before loading onto an Octyl-Sepharose column (Pharmacia) pre-
equilibrated with 24%(w/v) AS. This column was used for the puri-
®cation of C1A, Pre-N175A, Pre-C1S and Pre-C1A mutants. Since
both N175A and C1S mutants have a His tag at their C-termini,
puri®cation was carried out using Ni2+-bound chelating resin (Phar-
macia). The purity of the ®nal protein preparations was con®rmed
using SDS±PAGE, in which each preparation showed a single band.
The yield of the mutant proteins was 20 mg per litre of culture.
Penicillin V acylase activity was measured by reacting the 6-amino
group of the product 6-APA with p-dimethylaminobenzaldehyde to
yield a chromogenic Schiff base (Shewale et al., 1987).
2.3. Crystallization and data collection
Crystals used in data collection were grown using the hanging-drop
vapour-diffusion method, mixing an equal amount (1 ml) of protein at
a concentration of 20±25 mg mlÿ1 with the well solutions. Crystal-
lization studies were performed with a number of commercial
screens, including Crystal Screens (Hampton) and Clear Strategy
Screens (Molecular Dynamics Ltd). Beautiful crystals were obtained
in CSS-I condition 8 [0.2 M lithium sulfate and 15%(w/v) PEG 4K],
but had poor diffraction properties. The crystals of mutant PVA
proteins were successfully grown from conditions based on those
used for native PVA. The well solution contained 700 ml 0.2 M
sodium phosphate buffer pH 6.4 with 300 ml saturated AS and
100 ml 10%(w/v) sucrose solution. In some cases, the use of additional
additives gave rise to improved quality crystals (Table 1). The crys-
tallization temperature was 292 K. Diffraction data were collected
using synchrotron radiation at the European Synchrotron Radiation
Source (ESRF, Grenoble, France) or Synchrotron Radiation Source
(SRS, Daresbury, Warrington, UK) using CCD detectors. All data
were collected at 100 K under liquid nitrogen from crystals ¯ash-
cooled in the presence of 30%(v/v) glycerol or 1,2,6-hexanetriol
(Table 1). The diffraction data were processed and scaled using the
DENZO and SCALEPACK modules of the HKL package (Otwi-
nowski & Minor, 1997).
3. Results and discussion
The two residues targeted for mutation were Cys1 and Asn175.
Information based on studies of other Ntn hydrolases allowed us to
identify cysteine as acting as the nucleophile in PVA and thus it was
assumed that its mutation would affect the catalytic properties of the
enzyme. Structural comparison with other members of the family
helped to identify Asn175 in PVA as the oxyanion-hole residue
stabilizing the transition-state complex during catalysis. Mutating
these two functional residues to alanine resulted in loss of activity
towards penicillin V. Inclusion of the N-terminal tripeptide of the
precursor in each mutant was intended to assess the individual roles
of the mutated amino acids in the post-translational processing of
PVA. As stated in x1, some Ntn hydrolases are functional with a Ser
or Thr in the place of Cys as their catalytic centre. To test whether a
serine residue can functionally replace the cysteine in PVA, we
prepared a third pair of mutants by mutating Cys1 to Ser. Surpris-
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Table 1
Crystallization conditions for mutant PVA proteins.
The well-solution components and the cryoprotectant used are tabulated for each
mutant. PB, 200 mM sodium phosphate buffer pH 6.4; AS, saturated ammonium sulfate;
S, 10%(w/v) sucrose; M, 2 M maltose; DMSO, dimethyl sulfoxide; NC, 2 M nickel
chloride in PB; HXT, 1,2,6-hexanetriol.
Crystallization conditions
(ml component in well solution)
PVA mutant
Protein conc.
(mg mlÿ1) in H2O PB AS S M DMSO NC
Cryoprotectant
[30%(v/v)]
Pre-Cys1Ala 25 700 300 100 50 Ð Ð HXT
Cys1Ala 20 700 300 100 Ð Ð Ð Glycerol
Pre-Cys1Ser 20 700 300 100 Ð 50 Ð HXT
Cys1Ser 20 700 300 100 Ð Ð Ð HXT
Pre-Asn175Ala 25 650 350 100 Ð Ð Ð HXT
Asn175Ala 25 750 250 100 Ð Ð 25 HXT
Table 2
Protein-sequence analysis of PVA mutant enzymes.
`Pre-' indicates the presence of precursor tripeptide. Pre-Asn175Ala showed 50%
processing activity based on the products detected by N-terminal sequencing. The
proteins were pre-derivatized with acrylamide to allow detection of a stable Cys-adduct.
The site of mutation at the N-terminus is highlighted in bold. fMet indicates that
processing had occurred, probably by simple removal of the initiator methionine residue.
N-terminal sequence Activity
PVA/mutant Cloned gene Mature peptide Processed Catalytic
Native MLGCSS . . . CSS . . . Yes Yes
Pre-Cys1Ala MLGASS . . . MLGASS . . . No No
Pre-Cys1Ser MLGSSS . . . MLGSSS . . . No No
Pre-Asn175Ala MLGCSS . . . MLGCSS . . . + CSS . . . 50% No
Cys1Ser MSSS . . . SSS . . . fMet No
Cys1Ala MASS . . . ASS . . . fMet No
Asn175Ala MCSS . . . CSS . . . fMet No
ingly, this mutant also showed no activity towards penicillin V. Table 2
is a summary of N-terminal protein-sequence analysis of the puri®ed
mutant proteins. Recombinant PVA is processed normally when
expressed in E. coli, yielding a preparation whose speci®c activity
(30 U mgÿ1) resembled that of puri®ed enzyme from native sources
(Pundle & SivaRaman, 1997). All mutant proteins with the pro-
sequence retain the three amino acids Met-Leu-Gly and all mutant
constructs lacking the pro-sequence appear to have their initiation
formylmethionyl (fMet) residue removed. None of the mutant
proteins yielded active PVA and the N175A mutant led to both
processing and activity defects.
Initially, several different precipitants and buffers were used in
crystallization attempts. Often, the crystals were unstable or their
diffraction quality was poor. The only condition found that worked
well for all the mutants was 30% saturated AS as the precipitant in
sodium phosphate buffer pH 6.4 supplemented with sucrose (Table 1).
In the case of all three pairs of mutants, the crystals (Fig. 1) usually
appeared within a few days. The details of data collection and crystal
parameters for the mutants are summarized in Table 3. Curiously, all
the mutants crystallized in space groups that were different from that
of the native enzyme, although the crystallization conditions of the
wild-type enzyme and the mutants were almost identical. The crystals
of PVA mutant proteins (Fig. 1) are monoclinic, whereas native PVA
crystallized in space groups P65 and P1 (Suresh et al., 1999). They
diffracted to various resolutions (Table 3). Molecular-replacement
calculations using the PVA structure (PDB code 2pva) as a search
model showed that the asymmetric unit was constituted of a tetramer.
The crystals with a large unit cell (monoclinic form I, Table 3)
contained two tetramers in the asymmetric unit. Based on the above
information, the calculation of the Matthews coef®cient (Matthews,
1968) gave values almost equal in magnitude for all crystals and the
solvent content worked out as around 60% in all forms (Table 3). The
re®nement of the structures of all the mutants and investigations
towards understanding the mechanism of autoproteolytic activation
of PVA enzyme through structural analysis are in progress.
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Figure 1
(a) Monoclinic (form II) crystals of Pre-N175A precursor and (b) (form I) crystals
of N175A mutant proteins of B. sphaericus PVA.
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